RYBREVANT

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug RYBREVANT contains one active pharmaceutical ingredient (API):

1	Amivantamab UNII 0JSR7Z0NB6 - AMIVANTAMAB
	Amivantamab is a low-fucose, fully-human IgG1-based EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating EGFR Exon 20 insertion mutations. Amivantamab binds to the extracellular domains of EGFR and MET. Amivantamab disrupts EGFR and MET signalling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumour growth and progression.
	Read more about Amivantamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYBREVANT Solution for injection	MPI, US: SPL/PLR
RYBREVANT Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX18		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1868542
FI	Lääkealan turvallisuus- ja kehittämiskeskus	156701
FR	Base de données publique des médicaments	61371536
IL	מִשְׂרַד הַבְּרִיאוּת	9033
IT	Agenzia del Farmaco	049823014
LT	Valstybinė vaistų kontrolės tarnyba	1093863
PL	Rejestru Produktów Leczniczych	100463491
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68416001
US	FDA, National Drug Code	57894-501